UBS Initiates Coverage On CymaBay Therapeutics with Buy Rating, Announces Price Target of $18
Portfolio Pulse from richadhand@benzinga.com
UBS analyst Eliana Merle has initiated coverage on CymaBay Therapeutics (NASDAQ:CBAY) with a Buy rating and a price target of $18.
August 14, 2023 | 10:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS has initiated coverage on CymaBay Therapeutics with a Buy rating and a price target of $18, which could potentially boost the stock's performance.
The initiation of coverage by a major financial institution like UBS, coupled with a Buy rating and a price target of $18, indicates a positive outlook for CymaBay Therapeutics. This could potentially attract more investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100